Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: heart failure


Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes

February 2nd 2022

SGLT2i and SGLT2i/GLP-1RA combination regimens may be beneficial in primary prevention of MACCE and HF and GLP-1RA for HF. These data call for primary prevention trials using these agents and their combination (Diabetes Care)

Categories: Cardiovascular, Medication, News
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: GLP-1 receptor agonists, heart failure, SGLT2 inhibitors, Type 2 Diabetes

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors

January 27th 2022

The ESC recently added SGLT2 inhibitors to the management guidelines for HFrEF following good outcomes from DAPA-HF [18] and EMPEROR-Reduced [19] over the last 2 years. We hope that further supporting evidence for SGLT2 inhibitors in the management of HFpEF follows with the results of the ongoing DELIVER trial expected soon, and that as a result similar changes to guidelines may be added to support the use of SGLT2 inhibitors in the management of HFpEF (Diabetes Therapy)

Categories: Cardiovascular, Medication, News
Tags: heart failure, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: heart failure, SGLT2 inhibitors

Comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor-agonists: Scandinavian cohort study

November 7th 2021

Use of SGLT2 inhibitors vs GLP-1-receptor-agonists was associated with a similar risk of heart failure and lower risk of serious renal events while use of GLP-1-receptor-agonists vs SGLT2 inhibitors was associated with a slightly lower risk of MACE. In as-treated analyses, the associations with MACE and serious renal events increased in magnitude and the HR for heart failure tended towards a protective association for SGLT2 inhibitors (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: GLP-1 receptor agonists, heart failure, MACE, SGLT2 inhibitors

Categories: Cardiovascular, Medication, Nephropathy
Tags: GLP-1 receptor agonists, heart failure, MACE, SGLT2 inhibitors

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management

November 7th 2021

The aim of the review is to highlight the current perspectives of the pathophysiology of heart failure as it pertains to type 2 diabetes (Cardiovascular Diabetology)

Categories: Cardiovascular, Management, News
Tags: heart failure, Type 2 Diabetes

Categories: Cardiovascular, Management
Tags: heart failure, Type 2 Diabetes

Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status

November 5th 2021

In a new sub-analysis of the landmark EMPEROR-Preserved® phase III trial, Jardiance reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline (Boehringer Ingelheim and Eli Lilly)

Categories: Cardiovascular, Nephropathy, News
Tags: EMPEROR-Preserved, heart failure, Jardiance

Categories: Cardiovascular, Nephropathy
Tags: EMPEROR-Preserved, heart failure, Jardiance

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease

October 24th 2021

In this study, history of established ASCVD was associated with different hHF risks among SGLT2 inhibitors. For T2D patients without ASCVD, dapagliflozin may offer a more favorable hHF reduction effect, compared to empagliflozin, in clinical practice. Future prospective studies should be conducted to validate our findings (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: heart failure, SGLT2 inhibitors

Categories: Cardiovascular, Medication
Tags: heart failure, SGLT2 inhibitors

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

August 27th 2021

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes (NEJM)

Categories: Cardiovascular, Medication, News
Tags: Empagliflozin, heart failure

Categories: Cardiovascular, Medication
Tags: Empagliflozin, heart failure

Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

August 10th 2021

Amongst patients at risk for HF, those with diabetes have higher plasma concentrations of proteins involved in inflammation and proteolysis (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: heart failure, proteomics

Categories: Cardiovascular
Tags: heart failure, proteomics

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

August 1st 2021

The initiation of SGLT-2i as compared with other glucose-lowering drugs in routine clinical practice is associated with decreased risk of heart failure, all-cause death, myocardial infarction and stroke (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: heart failure, mortality

Categories: Cardiovascular, Medication
Tags: heart failure, mortality

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

November 17th 2020

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo (NEJM)

Categories: Cardiovascular, Medication, News
Tags: heart failure, sotagliflozin

Categories: Cardiovascular, Medication
Tags: heart failure, sotagliflozin

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients

May 31st 2020

Use of SGLT2i improved cardiac function in diabetic patients, regardless of the presence of HF. The improvements were more prominent in HF patients, especially in those with HFrEF. These improvements in cardiac function would contribute to the clinical benefit of SGLT2i (Cardiovascular Diabetology)

Categories: Medication, News
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

12‐Year Trends in Pharmacologic Treatment of Type 2 Diabetes among Patients with Heart Failure in the United States

January 6th 2020

Despite their promising cardiovascular safety profile, SGLT‐2i use remains relatively limited (Diabetes, Obesity and Metabolism)

Categories: News
Tags: heart failure, Type 2 Diabetes

Categories:
Tags: heart failure, Type 2 Diabetes

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

November 21st 2019

Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes (NEJM)

Categories: Medication, News
Tags: dapagliflozin, heart failure

Categories: Medication
Tags: dapagliflozin, heart failure

Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis

March 14th 2019

The predominant impact of SGLT-2i is on “hHF or CV mortality” composite driven predominantly by reduction in hHF and not atherosclerotic CV disease (Diabetes Therapy)

Categories: Medication, News
Tags: heart failure, SGLT2 inhibitors

Categories: Medication
Tags: heart failure, SGLT2 inhibitors

Heart failure among people with Type 2 diabetes mellitus: real‐world data of 289 954 people from a diabetes database

February 4th 2019

Heart failure is common in diabetes mellitus, but the prevalence in the DPV is lower frequent than expected. The reason for improved metabolic control in heart failure may be intensified therapy with insulin, lipid‐lowering medication and anti‐hypertensives in this cohort (Diabetic Medicine)

Categories: Cardiovascular, News
Tags: heart failure, insulin, Type 2 Diabetes

Categories: Cardiovascular
Tags: heart failure, insulin, Type 2 Diabetes

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus

June 25th 2018

This study helps further characterize the potential benefits and harms of SGLT2i in routine clinical practice to complement evidence from clinical trials and prior observational studies (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: heart failure, SGLT2 inhibitors, Type 2 Diabetes

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure

May 25th 2018

The beneficial effects of SGLT2 inhibitors on such outcomes and the heart itself are unique characteristics among antidiabetic agents, and SGLT2 inhibitors are expected to be a promising therapeutic option for CV disease and HF care (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: heart failure, SGLT2 inhibitors

Categories: Cardiovascular
Tags: heart failure, SGLT2 inhibitors

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

September 2nd 2017

In patients with T2D and established CVD, a sizeable proportion without HF at baseline are at high or very high risk for HF outcomes, indicating the need for active case finding in this patient population. Empagliflozin consistently improved HF outcomes both in patients at low or high HF risk (European Heart Journal)

Categories: Cardiovascular, News
Tags: Empagliflozin, heart failure

Categories: Cardiovascular
Tags: Empagliflozin, heart failure

Cardiac Stress and Inflammatory Markers as Predictors of Heart Failure in Patients With Type 2 Diabetes: The ADVANCE Trial

August 23rd 2017

Only NT-proBNP strongly and consistently improved the prediction of heart failure in patients with type 2 diabetes beyond a wide range of clinical risk factors and biomarkers (Diabetes Care)

Categories: Cardiovascular, News
Tags: heart failure, prediction, Type 2 Diabetes

Categories: Cardiovascular
Tags: heart failure, prediction, Type 2 Diabetes

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study

May 25th 2017

Predominantly male patients initiating treatment for diabetes mellitus with sulfonylurea had a higher risk of heart failure and cardiovascular death compared to similar patients initiating metformin (Journal of the American Academy of Heart Association)

Categories: Medication, News
Tags: heart failure, metformin, sulfonylureas

Categories: Medication
Tags: heart failure, metformin, sulfonylureas
  • 1
  • 2
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Boehringer IngelheimAstraZenecaNapp DiabetesNovo Nordisk

Silver Sponsors

About Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership